Whole Body Health Sale

Lupus: Systemic Lupus Erythematosus (SLE) References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Lupus Foundation of America. Understanding Lupus. 2011 8/11//2011]; Available from: http://www.lupus.org/clinicaltrials/understanding-lupus.html.
  2. Toloza, S.M., et al., Vitamin D insufficiency in a large female SLE cohort. Lupus, 2010. 19(1): p. 13-9.
  3. Lemire, J.M., Immunomodulatory role of 1,25-dihydroxyvitaminD3. Journal of cellular biochemistry, 1992. 49(1): p. 26-31.
  4. Damanhouri LH. Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med J. 2009. 30(10): p. 1291-5.
  5. Ritterhouse, L.L., et al., Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Annals of the rheumatic diseases, 2011. 70(9): p. 1569-74.
  6. Womenshealth.gov. Lupus Fact Sheet. 2011 9/24/2011]; Available from: http://www.womenshealth.gov/publications/our-publications/fact-sheet/lupus.cfm.
  7. Clowse, M.E., et al., A national study of the complications of lupus in pregnancy. American journal of obstetrics and gynecology, 2008. 199(2): p. 127 e1-6.
  8. Kwok, L.W., et al., Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus, 2011. 20(8): p. 829-36.
  9. Smyth, A. and V.D. Garovic, Systemic lupus erythematosus and pregnancy. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2009. 61(4): p. 457-74.
  10. Firestein, G.S. and W.N. Kelley, Kelley's textbook of rheumatology. 8th ed2009, Philadelphia, PA: Saunders/Elsevier.
  11. White, P.H., Pediatric systemic lupus erythematosus and neonatal lupus. Rheumatic diseases clinics of North America, 1994. 20(1): p. 119-27.
  12. Silverman, E. and E. Jaeggi, Non-cardiac manifestations of neonatal lupus erythematosus. Scandinavian journal of immunology, 2010. 72(3): p. 223-5.
  13. Wisuthsarewong, W., J. Soongswang, and R. Chantorn, Neonatal lupus erythematosus: clinical character, investigation, and outcome. Pediatric dermatology, 2011. 28(2): p. 115-21.
  14. Phillips, R.H., Coping with lupus : a guide to living with lupus for you and your family1991, Garden City Park, N.Y.: Avery Pub. Group. xii, 276 p.
  15. Griffiths, B., M. Mosca, and C. Gordon, Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best practice & research. Clinical rheumatology, 2005. 19(5): p. 685-708.
  16. Smith, P.P. and C. Gordon, Systemic lupus erythematosus: clinical presentations. Autoimmunity reviews, 2010. 10(1): p. 43-5.
  17. Bonelli M et al. Treg and lupus. Ann Rheum Dis. 2010 Jan;69Suppl1:i65-66.
  18. Bruce D et al. Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. IntImmunol. 2011 Aug;23(8):519-28. Epub 2011 Jun 22.
  19. 18a. Terrier B, Derian N, Schoindre Y, et al. Costedoat-Chalumeau N. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis research & therapy. Oct 17 2012;14(5):R221.

  20. Levey, A.S., et al., Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international, 2005. 67(6): p. 2089-100.
  21. Manzi, S., et al., Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. American journal of epidemiology, 1997. 145(5): p. 408-15.
  22. Trager, J. and M.M. Ward, Mortality and causes of death in systemic lupus erythematosus. Current opinion in rheumatology, 2001. 13(5): p. 345-51.
  23. Kahlenberg, J.M. and M.J. Kaplan, The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis research & therapy, 2011. 13(1): p. 203.
  24. Nowicka-Sauer, K., et al., Neuropsychological assessment in systemic lupus erythematosus patients: clinical usefulness of first-choice diagnostic tests in detecting cognitive impairment and preliminary diagnosis of neuropsychiatric lupus. Clinical and experimental rheumatology, 2011. 29(2): p. 299-306.
  25. Huizinga, T.W. and B. Diamond, Lupus and the central nervous system. Lupus, 2008. 17(5): p. 376-9.
  26. Muscal, E. and R.L. Brey, Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurologic clinics, 2010. 28(1): p. 61-73.
  27. Record, J.L., T. Beukelman, and R.Q. Cron, High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. Pediatric rheumatology online journal, 2011. 9: p. 20.
  28. MedlinePlus. CBC. 2010 09/04/11]; Available from: http://www.nlm.nih.gov/medlineplus/ency/article/003642.htm.
  29. McCrae, K.R., Thrombocytopenia. Basic and clinical oncology2006, New York: Taylor & Francis. xii, 315 p.
  30. Hochberg MC et al. American College of Rheumatology. American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. 1997 (Update from 1982) 09/04/11]; Available from: http://www.rheumatology.org/practice/clinical/classification/SLE/1997_update_of_the_1982_acr_revised_criteria_for_classification_of_sle.pdf.
  31. Cutolo M et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13(9):635-8.
  32. Shabanova SS et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. ClinExpRheumatol. 2008 May-Jun;26(3):436-41.
  33. Buyon JP, Petri MA, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med . 2005 Jun 21;142(pt 1):953-62.
  34. Walker SE et al. Accelerated deaths from systemic lupus erythematosus in NZB x NZWF1 mice treated with the testosterone-blocking drug flutamide. J Lab Clin Med. 1994;124(3):401-7.
  35. Kanda N et al. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1703-11.
  36. Gompel A et al. Systemic lupus erythematosus and hormone replacement therapy. Menopause Int. 2007 Jun;13(2):65-70.
  37. Doria, A., et al., Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Annals of the rheumatic diseases, 2003. 62(11): p. 1071-7.
  38. Cameron, J.S., Lupus nephritis. Journal of the American Society of Nephrology : JASN, 1999. 10(2): p. 413-24.
  39. Horizon, A.A. and D.J. Wallace, Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert opinion on drug safety, 2004. 3(4): p. 273-8.
  40. Bjarnason, I., et al., Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology, 1993. 104(6): p. 1832-47.
  41. Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res ClinRheumatol. 2005 Oct;19(5):823-38.
  42. Verheugt, F.W. and A.C. Bolte, The role of aspirin in women's health. International journal of women's health, 2011. 3: p. 151-66.
  43. Ben-Zvi, I., et al., Hydroxychloroquine: From Malaria to Autoimmunity. Clinical reviews in allergy & immunology, 2011.
  44. Chang, A.Y., et al., Response to Antimalarial Agents in Cutaneous Lupus Erythematosus: A Prospective Analysis. Archives of dermatology, 2011.
  45. Yildirim-Toruner, C. and B. Diamond, Current and novel therapeutics in the treatment of systemic lupus erythematosus. The Journal of allergy and clinical immunology, 2011. 127(2): p. 303-12; quiz 313-4.
  46. Mitwalli, A.H., et al., Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: A long-term randomized controlled trial. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2011. 22(5): p. 935-40.
  47. Walsh, M., et al., Mycophenolatemofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clinical journal of the American Society of Nephrology : CJASN, 2007. 2(5): p. 968-75.
  48. Shum, K. and A. Askanase, Treatment of lupus nephritis. Current Rheumatology Reports. 2011. 13(4): p. 283-90.
  49. Hahn, B.H., Targeted therapies in systemic lupus erythematosus: successes, failures and future. Annals of the rheumatic diseases, 2011. 70 Suppl 1: p. i64-i66.
  50. Houssiau, F.A., et al., Azathioprine versus mycophenolatemofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Annals of the rheumatic diseases, 2010. 69(12): p. 2083-9.
  51. Thanou-Stavraki, A. and A.H. Sawalha, An update on belimumab for the treatment of lupus. Biologics : targets & therapy, 2011. 5: p. 33-43.
  52. Food and Drug Administration (FDA). Medication Guide: Benlystaj (beliimumab) -- Injection for intravenous use. 2011 09/28/11]; Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM247030.pdf.
  53. Sabahi, R. and J.H. Anolik, B-cell-targeted therapy for systemic lupus erythematosus. Drugs, 2006. 66(15): p. 1933-48.
  54. Pollack A. "F.D.A. Panel Backs Drug for Lupus". New York Times 11/17/2010. Available at http://www.nytimes.com/2010/11/17/health/17drug.html.
  55. Haubitz, M., New and emerging treatment approaches to lupus. Biologics : targets & therapy, 2010. 4: p. 263-71.
  56. Illei, G.G., et al., Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Annals of the rheumatic diseases, 2011.
  57. Song, X.N., et al., Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients. Transplantation proceedings, 2011. 43(5): p. 1924-7.
  58. Gratwohl, A., et al., Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone marrow transplantation, 2005. 35(9): p. 869-79.
  59. Hyphantis, T., et al., Coping with health-stressors and defence styles associated with health-related quality of life in patients with systemic lupus erythematosus. Lupus, 2011. 20(9): p. 893-903.
  60. Greco, C.M., T.E. Rudy, and S. Manzi, Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis and rheumatism, 2004. 51(4): p. 625-34.
  61. Sanders, C.J., et al., Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. The British journal of dermatology, 2003. 149(1): p. 131-7.
  62. Kuhn, A., et al., Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. Journal of the American Academy of Dermatology, 2011. 64(1): p. 37-48.
  63. Chilibeck, P.D., D.G. Sale, and C.E. Webber, Exercise and bone mineral density. Sports medicine, 1995. 19(2): p. 103-22.
  64. Carvalho, M.R., et al., Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis and rheumatism, 2005. 53(6): p. 838-44.
  65. Ramsey-Goldman, R., et al., A pilot study on the effects of exercise in patients with systemic lupus erythematosus. Arthritis care and research : the official journal of the Arthritis Health Professions Association, 2000. 13(5): p. 262-9.
  66. Berdanier, C.D., J.T. Dwyer, and E.B. Feldman, Handbook of nutrition and food. 2nd ed2008, Boca Raton: Taylor & Francis. 1265 p.
  67. Cantorna, M.T. and B.D. Mahon, Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Experimental biology and medicine, 2004. 229(11): p. 1136-42.
  68. Amital, H., et al., Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Annals of the rheumatic diseases, 2010. 69(6): p. 1155-7.
  69. Borba, V.Z., et al., Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009. 20(3): p. 427-33.
  70. Kris-Etherton, P.M., et al., Polyunsaturated fatty acids in the food chain in the United States. The American journal of clinical nutrition, 2000. 71(1 Suppl): p. 179S-88S.
  71. Connor, W.E., Importance of n-3 fatty acids in health and disease. The American journal of clinical nutrition, 2000. 71(1 Suppl): p. 171S-5S.
  72. Iwami D, Nonomura K, Shirasugi N, et al. Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Int Immunopharmacol. 2011. 11(3): p. 384-9.
  73. Duffy, E.M., et al., The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. The Journal of rheumatology, 2004. 31(8): p. 1551-6.
  74. Walton, A.J., et al., Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Annals of the rheumatic diseases, 1991. 50(7): p. 463-6.
  75. Clark, W.F., et al., Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney international, 1993. 44(1): p. 75-86.
  76. Simopoulos AP. The importance if the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood). 2008. 233(6): p. 674-88.
  77. Singh, U., S. Devaraj, and I. Jialal, Vitamin E, oxidative stress, and inflammation. Annual review of nutrition, 2005. 25: p. 151-74.
  78. Ayres S Jr, Mihan R. Is vitamin E involved in the autoimmune mechanism? Cutis. 1978 Mar;21(3):321-5.
  79. Weimann BJ, Hermann D. Inhibition of autoimmune deterioration in MRL/lpr mice by vitamin E. Int J VitamNutr Res . 1999 Jul;69(4):255-61.
  80. Maeshima, E., et al., The efficacy of vitamin E against oxidative damage and autoantibody production in systemic lupus erythematosus: a preliminary study. Clinical rheumatology, 2007. 26(3): p. 401-4.
  81. Coates, P.M., Encyclopedia of dietary supplements, 2010, Informa Healthcare,: New York. p. 1 online resource (xix, 898 p.).
  82. Harbige, L.S., Nutrition and immunity with emphasis on infection and autoimmune disease. Nutrition and health, 1996. 10(4): p. 285-312.
  83. Bae, S.C., S.J. Kim, and M.K. Sung, Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Rheumatology international, 2002. 22(6): p. 238-43.
  84. Kurien, B.T., A. D'Souza, and R.H. Scofield, Heat-solubilized curry spice curcumin inhibits antibody-antigen interaction in in vitro studies: a possible therapy to alleviate autoimmune disorders. Molecular nutrition & food research, 2010. 54(8): p. 1202-9.
  85. Bright, J.J., Curcumin and autoimmune disease. Advances in experimental medicine and biology, 2007. 595: p. 425-51.
  86. Khajehdehi, P., et al., Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering from Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-controlled Study. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2011.
  87. McKenna, D.J., K. Jones, and K. Hughes, Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Alternative therapies in health and medicine, 2001. 7(5): p. 70-86, 88-90.
  88. Muir, A.H., et al., The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vascular medicine, 2002. 7(4): p. 265-7.
  89. Stefanescu, M., et al., Pycnogenol efficacy in the treatment of systemic lupus erythematosus patients. Phytotherapy research : PTR, 2001. 15(8): p. 698-704.
  90. Sawalha AH et al. Dehydroepiandrosterone in systemic lupus erythematosus. CurrRheumatol Rep. 2008 Aug;10(4):286-91.
  91. Chang, D.M., et al., Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism, 2002. 46(11): p. 2924-7.
  92. Chang, D.M., et al., Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Annals of the rheumatic diseases, 2004. 63(12): p. 1623-6.
  93. Nordmark G et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005 Nov;38(7):531-40.
  94. Hartkamp A et al. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum. 2004 Nov;50(11):3591-5.
  95. Montanaro, A. and E.J. Bardana, Jr., Dietary amino acid-induced systemic lupus erythematosus. Rheumatic diseases clinics of North America, 1991. 17(2): p. 323-32.
  96. Bardana, E.J., Jr., et al., Diet-induced systemic lupus erythematosus (SLE) in primates. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1982. 1(6): p. 345-52.
  97. Akaogi, J., et al., Role of non-protein amino acid L-canavanine in autoimmunity. Autoimmunity reviews, 2006. 5(6): p. 429-35.
  98. Barrett, B., Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. The Journal of pediatrics, 2004. 145(1): p. 135-6.
  99. Lee, A.N. and V.P. Werth, Activation of autoimmunity following use of immunostimulatory herbal supplements. Archives of dermatology, 2004. 140(6): p. 723-7.
  100. Spelman, K., et al., Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Alternative medicine review : a journal of clinical therapeutic, 2006. 11(2): p. 128-50.
  101. Chen YZ et al. Meta-analysis of Tripterygiumwilfordii Hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med. 2010;49(19):2049-55. Epub 2010 Oct 1.
  102. Huang GZ et al. [Pathological study on autopsy died of Tripterygium intoxication--report of 4 cases]. ZhongguoZhong Xi Yi Jie He ZaZhi. 2009 Feb;29(2):165-8.
  103. Wang BX et al. [A tablet of Tripterygiumwilfordii in treating lupus erythematosus]. Zhong Xi Yi Jie He ZaZhi. 1989 Jul;9(7):407-8, 389.
  104. Huang L et al. Decreased bone mineral density in female patients with systemic lupus erythematosus after long-term administration of TripterygiumWilfordii Hook. F. Chin Med J (Engl). 2000 Feb;113(2):159-61.
  105. NCCAM. National Center for Complementary and Alternative Medicine. "Thunder God Vine". Available at: http://nccam.nih.gov/health/tgvine/ Accessed 10/18/2011.